Subscriber access provided by READING UNIV
Article
Distribution of novel and well-known poly- and perfluoroalkyl substances (PFASs) in human serum, plasma, and whole blood Somrutai Poothong, Cathrine Thomsen, Juan Antonio Padilla Sanchez, Eleni Papadopoulou, and Line Småstuen Haug Environ. Sci. Technol., Just Accepted Manuscript • DOI: 10.1021/acs.est.7b03299 • Publication Date (Web): 22 Oct 2017 Downloaded from http://pubs.acs.org on October 26, 2017
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
Environmental Science & Technology is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 33
Environmental Science & Technology
Figure-1 500x139mm (96 x 96 DPI)
ACS Paragon Plus Environment
Environmental Science & Technology
Figure-2 200x500mm (96 x 96 DPI)
ACS Paragon Plus Environment
Page 2 of 33
Page 3 of 33
Environmental Science & Technology
Figure-3 500x179mm (96 x 96 DPI)
ACS Paragon Plus Environment
Environmental Science & Technology
Graphical Abstract 846x475mm (96 x 96 DPI)
ACS Paragon Plus Environment
Page 4 of 33
Page 5 of 33
Environmental Science & Technology
1
Distribution of novel and well-known poly- and perfluoroalkyl substances (PFASs) in
2
human serum, plasma, and whole blood
3 4
Somrutai Poothong,1* Cathrine Thomsen,1 Juan Antonio Padilla-Sanchez,1 Eleni
5
Papadopoulou,1 Line Småstuen Haug1
6 7
1
8
Health, P.O. Box 4404, Nydalen, NO-0403 Oslo, Norway.
Department of Environmental Exposure and Epidemiology, Norwegian Institute of Public
9 10
*Corresponding author:
11
Somrutai Poothong
12
Department of Environmental Exposure and Epidemiology, Norwegian Institute of Public
13
Health, P.O. Box 4404, Nydalen, NO-0403 Oslo, Norway
14
Phone number: +47 21076347
15
E-mail:
[email protected] 16 17
To be submitted to – Environmental Science and Technology
ACS Paragon Plus Environment
1
Environmental Science & Technology
18 19
Page 6 of 33
Abstract Currently, there is limited knowledge on the distribution of poly- and perfluoroalkyl
20
substances (PFASs) in different blood matrices, particularly for novel PFASs such as
21
polyfluoroalkyl phosphate esters (PAPs) and perfluoroalkyl phosphonates (PFPAs). To
22
explore this, serum, plasma, and whole blood from 61 adults in Oslo, Norway were collected.
23
The largest number of PFASs were detected in whole blood. For PAPs and PFPAs, the highest
24
frequencies of detection and concentrations were observed in plasma. PAPs contributed to 8%
25
of total PFASs in plasma (median, 0.81 ng mL-1). Perfluorohexylphosphonate (PFHxPA) was
26
the dominant PFPA, regardless of blood matrix. The relative composition profiles of PFASs in
27
blood matrices differed. For some specific PFASs such as perfluorooctanesulfonamide
28
(PFOSA) and perfluorohexanoate (PFHxA), the highest concentrations were observed in
29
whole blood. The PFAS concentration ratios varied between blood matrices, depending on the
30
compounds. However, similar ratios were observed for 6:2 polyfluoroalkyl phosphate diester
31
(6:2diPAP) as well as well-known PFASs such as perfluorooctanesulfonate (PFOS) and
32
perfluorooctanoate (PFOA). Besides the determination of twenty-five PFASs in human blood,
33
this study also lead to better understanding of biomonitoring data from different blood
34
matrices, which is key knowledge for performing both exposure assessments and
35
epidemiological studies.
ACS Paragon Plus Environment
2
Page 7 of 33
36 37
Environmental Science & Technology
Introduction Poly- and perfluoroalkyl substances (PFASs, CnF2n+1 −R) are a broad range of
38
synthetic organofluorine compounds based on two structural components, a hydrophobic
39
poly- or perfluoroalkyl chain, and a hydrophilic functional group (e.g. –COOH and –SO3H).
40
These unique molecules have been very useful in surfactant and polymer industries.1-2
41
However, their widespread use and unique physicochemical properties have also resulted in
42
their ubiquitous contamination of the environment, bioaccumulation in animals,3 and presence
43
in human blood all over the world.4-7 Most studies on PFASs so far have been limited to
44
perfluoroalkyl sulfonates (PFSAs, CnF2n+1SO3H) and perfluoroalkyl carboxylates (PFCAs,
45
CnF2n+1COOH), particularly in human blood.8
46
Associations between concentrations of some specific PFSAs and PFCAs in human
47
serum or plasma and a range of health outcomes have been observed in epidemiological
48
studies.9-11 Furthermore, a range of toxicological effects have been observed in animal studies
49
including tumor development, hormonal effects, and immunotoxicity.12-13 Based on its
50
persistence in the environment as well as the bioaccumulation and toxicological potential, use
51
of perfluorooctanesulfonate (PFOS) has been banned or restricted worldwide.14-16
52
Perfluorooctanoate (PFOA) has been identified as a substance of very high concern (SVHC)
53
in the REACH regulation and has been banned in consumer products in Norway.17 Following
54
such measures for some of the well-known PFASs, a shift towards production of short-chain
55
PFSAs/PFCAs and other functional groups such as polyfluoroalkyl phosphate esters (PAPs)
56
and perfluoroalkyl phosphonates (PFPAs) has occured.18-19 Previous studies have found that
57
the well-known PFSAs and PFCAs accounted for only 33–85% of total extractable organic
58
fluorine in whole blood of general populations.20-21 Thus, there are other PFASs in human
59
blood but so far, few biomonitoring studies have assessed the exposure to for instance PFAS
60
precursors and novel PFASs due to methodological limitations of chemical analyses.
ACS Paragon Plus Environment
3
Environmental Science & Technology
61
PFPAs (CnF2n+1P(O)(OH)2) are emerging PFASs and belong to the class of
62
perfluoroalkyl acids (PFAAs) along with PFSAs and PFCAs. PFPAs have been detected in
63
the environment, such as in surface water22 and wastewater,23 but also in indoor dust.24 Wang
64
et al. recently compared PFPAs to PFSAs and PFCAs and found similarities in persistence
65
and elimination potential in rainbow trout and rats.25 A limited number of studies have
66
included PFPAs, but there is a particular need for data on PFPAs in the same samples as of
67
PFSAs and PFCAs. Previous studies have reported that human body burden of PFASs also
68
occurs through indirect exposure to PFAS precursors, such as PAPs and perfluoroalkyl
69
sulfonamides (FOSAs). PAPs are surfactants possessing at least one polyfluoroalkyl tail,
70
F(CF2)nCH2CH2, and are mainly used in paper food packaging.26 Biotransformation of PAPs
71
into PFCAs has been observed in rats.27-28 In vivo animal experiments have also reported
72
biotransformation of FOSAs to PFOS.29
Page 8 of 33
73
Blood is an important and favorable matrix for determining the internal dose of
74
PFASs, and serum and plasma are most frequently used due to practical considerations, rather
75
than favorable partitioning of PFASs. However, to back calculate PFAS concentrations in
76
serum/plasma to whole blood, knowledge on the distribution of PFASs in the different blood
77
matrices is crucial. Whole blood consists of cellular elements (~45%) suspended in plasma
78
(liquid component, ~55%). If whole blood is allowed to clog and then centrifuged, about 30–
79
50% of the volume is serum/plasma, depending on anticoagulants. If it is correct that the
80
PFAS concentrations obtained in whole blood are approximately half those in serum/plasma it
81
can be assumed that PFASs are distributed mainly to the serum/plasma and to a limited extent
82
to the blood cells. However, as human blood is a complex mixture, also plasma and serum are
83
distinct fractions of whole blood. Plasma contains fibrinogen and has a higher total protein
84
content than serum, whereas serum has a higher concentration of some important protein and
85
platelet.30 In addition, different PFASs are known to have different physicochemical
ACS Paragon Plus Environment
4
Page 9 of 33
Environmental Science & Technology
86
properties and different binding affinities to blood.31 Limiting the analyses of PFASs to
87
serum/plasma might exclude the possible amount present in blood cells, and thus
88
underestimate the body burden. It should be emphasized that determination of PFASs in both
89
human serum, plasma, and whole blood from the same individual has seldom been carried out.
90
This is particularly true for novel PFASs, while some few studies have emphasized this aspect
91
for some well-known PFASs (e.g. PFOS, PFOA, perfluorohexanesulfonate (PFHxS),
92
perfluorononanoate (PFNA), and perfluorooctanesulfonamide (PFOSA)).32-34 Some studies
93
have only considered the partitioning between plasma and whole blood,32, 34-35 and/or included
94
only small and specific groups of the population (e.g. occupational, maternal).32-34 However,
95
knowledge on distributions between different blood matrices is important when performing
96
risk assessments, and can be of high importance when evaluating the possibilities of reverse
97
causations in epidemiological studies.
98 99
The aims of the present study were to assess the presence, concentrations, composition profiles, and correlations of various PFASs in whole blood, plasma and serum in a study
100
group of the general adult population. Further, correlations and distribution ratios between
101
different blood matrices were determined for each of the PFASs. Apart from measuring the
102
well-known PFASs such as PFSAs, PFCAs, and FOSAs, this study also included novel
103
PFASs such as PAPs and PFPAs for which this information is lacking entirely.
ACS Paragon Plus Environment
5
Environmental Science & Technology
104
Materials and methods
105
Study population
106
Page 10 of 33
During winter 2013–2014, 61 women and men living in the Oslo area, Norway were
107
enrolled in the Advanced Tools for Exposure Assessment and Biomonitoring (A-TEAM)
108
project,36 where serum, plasma, and whole blood were obtained. The participants comprised
109
45 women and 16 men (~75% women) between the age of 20 and 66 years old, with a median
110
age of 41 years. The Regional Committees for Medical and Health Research Ethics in Norway
111
(2013/1269) approved the sampling campaign of the A-TEAM project. In addition, all
112
participants gave a written consent before participating.
113 114 115
Sample collection Blood samples were drawn from a single venipuncture site. Whole blood samples were
116
collected in K2-ethylenediaminetetraacetic acid (EDTA) anticoagulant vacutainer tubes
117
(Becton, Dickinson and Company, Plymouth, UK). After a fraction of the whole blood was
118
transferred to a 2 mL polypropylene tube, the remaining blood in the EDTA vacutainer tube
119
was left to clot for one hour, centrifuged for 15 min at 2200-2500 rpm and then plasma was
120
transferred to a PP bottle. Vacutainer tubes without anticoagulant were used to collect blood
121
to obtain serum from the participants. The blood in the vacutainer tube without anticoagulant
122
was left to clot for one hour, centrifuged for 15 min at 2200-2500 rpm and then serum was
123
transferred to a PP bottle. All samples were stored at -20°C until further analysis.
124 125
Chemicals and standards
126
The twenty-five PFASs included in this study were 6:2 polyfluoroalkyl phosphate monoester
127
(6:2PAP), 8:2 polyfluoroalkyl phosphate monoester (8:2PAP), 6:2 polyfluoroalkyl phosphate
128
diester (6:2diPAP), 8:2 polyfluoroalkyl phosphate diester (8:2diPAP),
ACS Paragon Plus Environment
6
Page 11 of 33
Environmental Science & Technology
129
perfluorohexylphosphonate (PFHxPA), perfluorooctylphosphonate (PFOPA),
130
perfluorodecylphosphonate (PFDPA), perfluorobutanesulfonate (PFBS), PFHxS,
131
perfluoroheptanesulfonate (PFHpS), PFOS, perfluorodecanesulfonate (PFDS),
132
perfluoropentanoate (PFPeA), perfluorohexanoate (PFHxA), perfluoroheptanoate (PFHpA),
133
PFOA, PFNA, perfluorodecanoate (PFDA), perfluoroundecanoate (PFUnDA),
134
perfluorododecanoate (PFDoDA), perfluorotridecanoate (PFTrDA), perfluorotetradecanoate
135
(PFTeDA), PFOSA, N-methyl perfluorooctanesulfonamide (MeFOSA), and N-ethyl
136
perfluorooctanesulfonamide (EtFOSA). Details on the twenty-five native PFASs and eleven
137
isotope-labeled internal standards are given in Table S1 of supporting information. Since
138
PFSAs and PFCAs have been detected in human blood worldwide, but analyses of their
139
precursors have seldom been performed. Thus, this study included PFSA and PFCA
140
precursors, which were FOSAs and PAPs, respectively. In contrast, no studies have so far
141
detected PFPAs in human blood, and therefore only PFPAs were selected in this study, not
142
their precursors compounds (i.e. PFPiAs).
143 144 145
Blood analysis PFAS concentrations in serum, plasma, and whole blood samples were determined
146
using an established method by Poothong et al.37 Briefly, 50 µL of blood (serum, plasma, or
147
whole blood) was added to a 2 mL centrifuge tube, and then 90 µL of a 5 ng mL-1 internal
148
standard solution and 90 µL of methanol were added. To precipitate the proteins, the sample
149
tubes were mixed on a whirl mixer and centrifuged for 40 min at 14000 rpm at 20°C. The
150
supernatant was transferred to a 250 µL polypropylene vial, and then 80 µL of the sample was
151
injected in an online-SPE-UHPLC-MS/MS system.
152 153
Quality assurance/quality control
ACS Paragon Plus Environment
7
Environmental Science & Technology
154
Page 12 of 33
Duplicate matrix-matched calibration standards were prepared in twelve different
155
concentrations in the range 0.006–45 ng mL-1 blood. Newborn calf serum (Invitrogen, Oslo,
156
Norway), calf plasma, and calf whole blood (Lampire Biological labs, Pipersville, USA) were
157
used for the preparation of the matrix-matched calibration standards for serum, plasma, and
158
whole blood analysis, respectively. The matrix-matched calibration standards were injected
159
before and after the samples to ensure linearity in instrument response during the analysis and
160
for monitoring possible drifts in the sensitivity. Quantification was performed using
161
concentration-weighted (1/concentration) linear regression. For quantification of PFOS, the
162
total area of linear and branched isomers was integrated. Three solvent procedure blanks and
163
three non-spiked calf serum, calf plasma or calf whole blood were included in the analysis to
164
monitor the PFASs background levels. To assure high quality of the determinations, in-house
165
quality control samples of human plasma and whole blood as well as human serum samples
166
from an interlaboratory comparison study (Arctic Monitoring and Assessment Programme,
167
AMAP) (n = 3) were analyzed along with the human serum, plasma, and whole blood
168
samples. The results of the serum, plasma, and whole blood quality control samples were
169
similar to the previous results of the application in method developments (lower than 15%
170
relative standard deviations, RSD).37 More details on the quality assurance and quality control
171
including assessment of method accuracy, repeatability, precision, and method detection
172
limits can be found in Poothong et al.37
173 174 175
Data analysis To calculate mean and median concentrations, concentrations below the method
176
detection limits (MDLs) were replaced with their MDLs divided by the square root of two
177
(MDL/√2), while values between the MDLs and method quantification limits (MQLs) were
178
used unaltered. This approach was also employed when evaluating the composition profiles
ACS Paragon Plus Environment
8
Page 13 of 33
Environmental Science & Technology
179
and correlations in the matrices. A Mann-Whitney U-test was used to assess differences in
180
PFAS concentrations between genders and to compare current levels with concentrations
181
reported in another similar study from Norway. Statistically significant differences in PFAS
182
concentrations with respect to age-tertiles were evaluated using a Kruskal-Wallis test.
183
Correlations between compounds were evaluated with Spearman's rank correlation coefficient
184
(rho) and tested for significance.
185
To evaluate the distribution ratio of PFASs between different blood matrices, only
186
paired samples from individuals with quantifiable concentrations (>MDL) in serum, plasma,
187
and whole blood were included. Since the PFAS concentration ratios between serum, plasma,
188
and whole blood are expected to be similar in all individuals, correlations between PFAS
189
concentrations in pairs of blood matrices were evaluated using Pearson correlation (pairwise
190
comparison) and tested for significance. A Wilcoxon signed ranks test was used for assessing
191
the statistically significant differences of PFASs in different blood matrices.
192
P-values < 0.05 were considered significant in all statistical tests. A Shapiro-Wilk W
193
test was used to test the data for normality. Statistical analyses were performed by using the
194
SPSS 23 software, except heat-map correlation plots which were made using the corrgram
195
package in R version 3.2.2.38, 39
ACS Paragon Plus Environment
9
Environmental Science & Technology
196
Results and discussion
197
Detection frequencies and concentrations of PFASs in serum, plasma, and whole blood
198
Page 14 of 33
Twenty-one of the twenty-five PFASs were detected in blood samples, although the
199
detection frequencies varied depending on the compounds and the blood matrices. PFHxS,
200
PFHpS, PFOS, PFOA, and PFNA were detected in all serum (n=61), plasma (n=59), and
201
whole blood (n=58) samples. Approximately 50–100% of all blood matrices had detectable
202
concentrations of 6:2diPAP, PFHxPA, PFBS, PFDS, PFDA, PFUnDA, PFDoDA, PFTrDA,
203
and PFOSA, while the detection frequency was more than 50% in some of the blood matrices
204
for 6:2PAP, PFHxA, and PFTeDA as shown in Table 1. No samples had PFDPA, PFPeA,
205
MeFOSA, and EtFOSA levels above their respective MDLs (0.0036–0.09 ng mL-1) (Table
206
S2), while 8:2diPAP, PFHpA were detected in all matrices but in less than 50% of the
207
samples.
208 209
PAPs
210
Among the PAPs, 6:2diPAP had the highest detection frequency in all blood matrices
211
(49–98%, plasma>whole blood>serum). 6:2PAP and 8:2diPAP were observed in 3–73% and
212
21–30% of the samples in all blood matrices, respectively, whereas 8:2PAP was detected only
213
in 5% of the whole blood samples. Interestingly, 6:2PAP was present in 73% of the plasma
214
samples while it has never been reported in human blood before. Very few studies have
215
previously determined the concentrations of PAPs in human blood, and most of them assessed
216
only serum. Detection frequencies of serum diPAPs in the present study were comparable to
217
other studies of PAPs in serum.6, 40 The serum concentrations of 6:2PAP, 6:2diPAP, and
218
8:2diPAP in this present study were in range of PFPAs of equal perfluorocarbon chain length.47 Assuming similar bioaccumulation
242
potentials in humans, the low levels of PFPAs in blood samples might be due to a fast
243
elimination rate in human body. However, to obtain more knowledge on this, assessments of
244
human exposure pathways for PAPs and PFPAs are needed. In addition, the relatively low
ACS Paragon Plus Environment
11
Environmental Science & Technology
Page 16 of 33
245
levels of PAPs and PFPAs observed in this study indicates that there is still a large amount of
246
organofluorine compounds in blood which are unidentified.21
247 248 249
PFSAs, PFCAs, and FOSAs Interestingly, PFHxA was detected in 100% of the whole blood samples while it was
250
not detected in any of the other blood matrices. This suggests that whole blood is the only
251
suitable blood matrix for determination of PFHxA, and that the exposure to PFHxA is
252
overlooked when assessing serum or plasma. These findings are in line with several recent
253
studies where PFHxA was not detected, or found in very few samples when assessing
254
serum/plasma.6, 42, 48-49
255
PFOSA was the only FOSA detected in any of the blood matrices (71–100%, whole
256
blood>serum>plasma), where the concentrations in whole blood were approximately one
257
order of magnitude higher than the ones in serum and plasma. The reason for detecting
258
PFOSA and PFHxA in higher frequencies and concentrations in whole blood compared to
259
serum and plasma is likely due to binding of the compounds to blood cells.
260
To assess time trends of PFSA s and PFCAs, levels from this study were compared to
261
a previous Norwegian study where samples were collected in 2007–2008 (41 women, age 28–
262
46, median 36).45 A significant decrease in the median PFOS concentration of around 35%
263
was observed (Figure S1). Surprisingly, no statistical significant change was observed for
264
PFOA (Mann-Whitney U test, p>0.05), even though PFOS and PFOA have comparable
265
elimination half-lives (PFOS: 4.8 years, PFOA: 3.5 years).50 Thus, either the exposure to
266
PFOA has not changed to the same extent as PFOS, or the direct PFOA exposure has
267
decreased but the indirect exposure through the biotransformation of precursor compounds to
268
PFOA has substantially increased. In addition, for PFUnDA no statistical change in the serum
269
concentrations was observed between the 2007/2008 study and the recent study. On the other
ACS Paragon Plus Environment
12
Page 17 of 33
Environmental Science & Technology
270
hand, increasing PFAS concentrations were observed between 2007/2008 and 2013/2014 for
271
PFHpS (74%), PFHxS (53%), PFDA (45%), and PFNA (31%). Increasing concentrations of
272
some long-chain PFCAs such as PFNA, PFDA, and PFUnDA have also been reported in
273
recent time trend studies in Danmark,51 Sweden,41, 52 and Japan.53 PAPs are metabolized into
274
long-chain PFCAs.27, 43 Thus despite direct exposure, the increasing levels of these long-chain
275
PFCAs might also relate to the indirect exposure from PAPs, which are still used in consumer
276
products.
277
Several studies have determined PFSAs, PFCAs, and FOSAs in human blood. PFOS
278
serum concentrations in the present study (median, 5.2 ng mL-1) were comparable to studies
279
from Sweden (2012)41 and Denmark (2008-2013),51 while studies in Australia (2010-2011)54
280
and the U.S. (2009)40 found PFOS concentrations in serum which were two times higher than
281
in this study. On the other hand, the PFOS median concentration reported in a study from
282
China (2009) was approximately half of that of the present study.42 The median serum
283
concentration of PFOA was 1.9 ng mL-1, which is similar to recent studies from the U.S.40 and
284
Denmark,51 while it was two times lower than in Australia.54 This study found similar median
285
serum concentrations of PFNA (0.9 ng mL-1), PFDA (0.4 ng mL-1), and PFUnDA (0.4 ng mL-
286
1
287
levels varied among the studies.
) as studies from the U.S.,40 Australia,54 Sweden,41 Denmark,51 and China,42 while PFHxS
288 289
PFAS profiles in serum, plasma, and whole blood
290
The relative composition profiles of PFASs in serum, plasma, and whole blood was
291
evaluated for PFASs with detection frequencies above 50% in each blood matrix (Table 1).
292
Total PFAS concentrations (ΣPFASs) were 10, 10, and 6.3 ng mL-1 in serum, plasma, and
293
whole blood, respectively. Significant difference of PFAS concentrations between ages and
294
genders were assessed. In whole blood, PFHxS, PFHpS, and PFOS concentrations in women
ACS Paragon Plus Environment
13
Environmental Science & Technology
295
were significantly lower than in men (Mann−Whitney U test, p ≤ 0.005, 2-tailed) (Table S3),
296
which is possibly linked to menstruation. Based on a pharmacokinetic model, menstruation
297
accounted for 30% of the difference in PFOS elimination between genders.55 No statistically
298
significant difference was observed between genders in the other compounds.
299
Page 18 of 33
The oldest age group (age-tertiles, 45) had significantly higher PFOA,
300
PFNA, PFDA, PFUnDA, PFTeDA, PFDS, and PFOSA concentrations in blood compared to
301
the other two age groups (Kruskal-Wallis test, p ≤ 0.05), while this was not the case for the
302
other compounds. The median relative PFAS compositions (ng mL-1) in serum, plasma, and whole blood
303 304
were all dominated by PFOS, followed by PFOA (Figure 1). The sum of PFOA and PFOS
305
contributed to 60–70% of the total PFAS concentrations. The contribution of PFPAs and
306
PAPs to the total PFAS concentrations in human blood were relatively low, and thus the
307
major fluorinated contaminants measured in this study in human blood are still PFSAs and
308
PFCAs. The PFAS composition profiles in serum and plasma were similar, with the
309
proportion of PFOS (48–51%) > PFOA (16-19%) > PFNA ≈ PFHxS (7–9%) > PFUnDA ≈
310
PFDA (3–4%) > PFHpS ≈ PFHxPA (2–3%) > PFTrDA ≈ PFDoDA ≈ PFDS ≈ PFBS ≈
311
PFOSA (1%). The 6:2diPAP contributed to 1% in plasma. Also the low detection frequency
312
PAP congener, 6:2PAP contributed to a greater percentage in plasma by 7%. Consequently, in
313
this study plasma proved to be a relevant matrix to quantifying PAPs and PFPAs in human
314
blood.
315
The relative composition of various PFASs in whole blood differed from serum and
316
plasma. PFHxA was only detected in whole blood, where it accounted for as much as 10% of
317
the total PFAS concentrations. Thus the composition profile of PFASs in whole blood was
318
PFOS (45%) > PFOA (15%) > PFHxA (10%) > PFNA ≈ PFHxS (6–7%) > PFUnDA ≈ PFDA
319
≈ PFTrDA ≈ PFOSA (2–3%) > PFTeDA ≈ PFDoDA ≈ PFDS ≈ PFHpS ≈ PFBS ≈ PFHxPA ≈
ACS Paragon Plus Environment
14
Page 19 of 33
Environmental Science & Technology
320
6:2diPAP (1%). Interestingly, whole blood was the matrix where the largest number of PFASs
321
was detected (16 PFASs), while serum and plasma have been the most frequently used
322
matrices in biomonitoring studies. In accordance with these differing PFAS profiles in serum,
323
plasma, and whole blood, epidemiological studies need to be taken into consideration when
324
associating PFASs levels in the blood with the health outcome.
325 326 327
Correlations between PFASs within the same blood matrix Correlations between different PFASs (detection frequency >50%) within the same
328
blood matrix were evaluated based on Spearman's rank correlation coefficients, and are
329
presented in Figure 2. Both weak positive and negative correlations were observed between
330
PAPs, as well as PFHxA with the other PFASs. However, weak but significant correlations
331
were observed between 6:2diPAP and PFHxA in whole blood (rs = 0.38, p